Breast cancer cells can switch between estrogen receptor α and ErbB signaling and combined treatment against both signaling pathways postpones development of resistance

Breast Cancer Research and Treatment

Volumn 121, Issue 3, 2010, Pages 601-613

  Sonne Hansen, Katrine ^a   Norrie, Ida C ^a   Emdal, Kristina B ^a   Benjaminsen, Rikke V ^a   Frogne, Thomas ^a   Christiansen, Ib J ^b   Kirkegaard, Tove ^a   Lykkesfeldt, Anne E ^a  

^a DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

^b FINSEN LABORATORY   (Denmark)

Author keywords

Breast cancer; CI 1033; Combined treatment; ER ; ErbB; Fulvestrant; Treatment resistance

Indexed keywords

3 [8 [(DIMETHYLAMINO)METHYL] 6,7,8,9 TETRAHYDROPYRIDO[1,2 A]INDOL 10 YL] 4 (1 METHYL 1H INDOL 3 YL) 1H PYRROLE 2,5 DIONE; CANERTINIB; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; ESTROGEN RECEPTOR ALPHA; FULVESTRANT; GROWTH FACTOR; HEREGLULIN 1BETA; MITOGEN ACTIVATED PROTEIN KINASE; PERTUZUMAB; PROTEIN KINASE B; PROTEIN KINASE B INHIBITOR; SH 6; TRASTUZUMAB; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER RESISTANCE; CELL STRAIN MCF 7; CONTROLLED STUDY; DRUG SELECTIVITY; DRUG SENSITIVITY; DRUG TARGETING; ENZYME INHIBITION; GROWTH INHIBITION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; FEMALE; HUMANS; MORPHOLINES; ONCOGENE PROTEINS V-ERBB; SIGNAL TRANSDUCTION;

EID: 77953119642     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-009-0506-y     Document Type: Article

References (54)

1. Brünner N, Frandsen TL, Holst-Hansen C, Bei M, Thompson EW, Wakeling AE, Lippman ME, Clarke R (1993) MCF7/LCC2: a 4-hydroxytamoxifen resistant human breast cancer variant that retains sensitivity to the steroidal antiestrogen ICI 182, 780. Cancer Res 53:3229-3232
2. Lykkesfeldt AE, Madsen MW, Briand P (1994) Altered expression of estrogen-regulated genes in a tamoxifen-resistant and ICI 164, 384 and ICI 182, 780 sensitive human breast cancer cell line, MCF-7/TAMR-1, Cancer Res 54:1587-1595
3. Howell A, DeFriend D, Robertson J, Blarney R, Walton P (1995) Response to a specific antioestrogen (ICI 182780) in tamoxifenresistant breast cancer. Lancet 345:29-30
4. Osborne CK, Wakeling A, Nicholson RI (2004) Fulvestrant: an oestrogen receptor antagonist with a novel mechanism of action. Br J Cancer 90(Suppl 1):S2-S6
5. McClelland RA, Barrow D, Madden TA, Dutkowski CM, Pamment J, Knowlden JM, Gee JM, Nicholson RI (2001) Enhanced epidermal growth factor receptor signaling in MCF7 breast cancer cells after long-term culture in the presence of the pure antiestrogen ICI 182, 780 (Faslodex). Endocrinology 142:2776-2788
6. Atlas E, Cardillo M, Mehmi I, Zahedkargaran H, Tang C, Lupu R (2003) Heregulin is sufficient for the promotion of tumorigenicity and metastasis of breast cancer cells in vivo. Mol Cancer Res 1:165-175 (Pubitemid 36330198)
7. Sommer A, Hoffmann J, Lichtner RB, Schneider MR, Parczyk K (2003) Studies on the development of resistance to the pure antiestrogen faslodex in three human breast cancer cell lines. J Steroid Biochem Mol Biol 85:33-47
8. Progne T, Jepsen JS, Larsen SS, Fog CK, Brockdorff BL, Lykkesfeldt AE (2005) Antiestrogen-resistant human breast cancer cells require activated protein kinase B/Akt for growth. Endocr Relat Cancer 12:599-614
9. Massarweh S, Osborne CK, Jiang S, Wakeling AE, Rimawi M, Mohsin SK, Hilsenbeck S, Schiff R (2006) Mechanisms of tumor regression and resistance to estrogen deprivation and fulvestrant in a model of estrogen receptor-positive, HER-2/neu-positive breast cancer. Cancer Res 66:8266-8273
10. Fan M, Yan PS, Hartman-Frey C, Chen L, Paik H, Oyer SL, Salisbury JD, Cheng AS, Li L, Abbosh PH, Huang TH, Nephew KP (2006) Diverse gene expression and DNA methylation profiles correlate with differential adaptation of breast cancer cells to the antiestrogens tamoxifen and fulvestrant. Cancer Res 66:11954-11966
11. Progne T, Benjaminsen RV, Sonne-Hansen K, Sorensen BS, Nexo E, Laenkholm AV, Rasmussen LM, Riese DJ, de CP, Stenvang J, Lykkesfeldt AE (2009) Activation of ErbB3, EGFR and Erk is essential for growth of human breast cancer cell lines with acquired resistance to fulvestrant. Breast Cancer Res Treat 114:263-275
12. Hobday TJ, Perez EA (2005) Molecularly targeted therapies for breast cancer. Cancer Control 12:73-81
13. Stern DF (2008) ERBB3/HER3 and ERBB2/HER2 duet in mammary development and breast cancer. J Mammary Gland Biol Neoplasia 13:215-223
14. Massarweh S, Schiff R (2006) Resistance to endocrine therapy in breast cancer: exploiting estrogen receptor/growth factor signaling crosstalk. Endocr Relat Cancer 13(Suppl 1):S15-S24
15. Pancholi S, Lykkesfeldt AE, Hilmi C, Banerjee S, Leary A, Drury S, Johnston S, Dowsett M, Martin LA (2008) ERBB2 influences the subcellular localization of the estrogen receptor in tamoxifenresistant MCF-7 cells leading to the activation of AKT and RPS6KA2. Endocr Relat Cancer 15:985-1002
16. Liu Y, el-Ashry D, Chen D, Ding IY, Kern FG (1995) MCF-7 breast cancer cells overexpressing transfected c-erbB-2 have an in vitro growth advantage in estrogen-depleted conditions and reduced estrogen-dependence and tamoxifen-sensitivity in vivo. Breast Cancer Res Treat 34:97-117
17. Stoica A, Saceda M, Doraiswamy VL, Coleman C, Martin MB (2000) Regulation of estrogen receptor-alpha gene expression by epidermal growth factor. J Endocrinol 165:371-378 (Pubitemid 30341086)
18. Oh AS, Lorant LA, Holloway JN, Miller DL, Kern FG, el-Ashry D (2001) Hyperactivation of MAPK induces loss of ERalpha expression in breast cancer cells. Mol Endocrinol 15:1344-1359
19. Bayliss J, Hilger A, Vishnu P, Diehl K, el-Ashry D (2007) Reversal of the estrogen receptor negative phenotype in breast cancer and restoration of antiestrogen response. Clin Cancer Res 13:7029-7036
20. Houston SJ, Plunkett TA, Barnes DM, Smith P, Rubens RD, Miles DW (1999) Overexpression of c-erbB2 is an independent marker of resistance to endocrine therapy in advanced breast cancer. Br J Cancer 79:1220-1226
21. Arpino G, Weiss H, Lee AV, Schiff R, De PS, Osborne CK, Elledge RM (2005) Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance. J Natl. Cancer Inst 97:1254-1261 (Pubitemid 41535366)
22. De Laurentiis M, Arpino G, Massarelli E, Ruggiero A, Carlomagno C, Ciardiello F, Tortora G, D'Agostino D, Caputo F, Cancello G, Montagna E, Malorni L, Zinno L, Lauria R, Bianco AR, De PS (2005) A meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer. Clin Cancer Res 11:4741-4748
23. Rasmussen BB, Regan MM, Lykkesfeldt AE, Dell'Orto P, Del CB, Henriksen KL, Mastropasqua MG, Price KN, Mery E, Lacroix-Triki M, Braye S, Altermatt HJ, Gelber RD, CastiglioneGertsch M, Goldhirsch A, Gusterson BA, Thurlimann B, Coates AS, Viale G (2008) Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial. Lancet Oncol 9:23-28
24. Lykkesfeldt AE, Larsen SS, Briand P (1995) Human breast cancer cell lines resistant to pure anti-estrogens are sensitive to tamoxifen treatment. Int J Cancer 61:529-534
25. Slichenmyer WJ, Elliott WL, Fry DW (2001) CI-1033, a panerbB tyrosine kinase inhibitor. Semin Oncol 28:80-85
26. Allen LF, Lenehan PF, Eiseman IA, Elliott WL, Fry DW (2002) Potential benefits of the irreversible pan-erbB inhibitor, CI-1033, in the treatment of breast cancer. Semin Oncol 29:11-21
27. Nelson JM, Fry DW (2001.) Akt, MAPK (Erk1/2), and p38 act in concert to promote apoptosis in response to ErbB receptor family inhibition. J Biol Chem 276:14842-14847
28. Allen LF, Eiseman IA, Fry DW, Lenehan PF (2003) CI-1033, an irreversible pan-erbB receptor inhibitor and its potential application for the treatment of breast cancer. Semin Oncol 30:65-78
29. Rixe O, Franco SX, Yardley DA, Johnston SR, Martin M, Arun BK, Letrent SP, Rugo HS (2009) A randomized, phase II, dosefinding study of the pan-ErbB receptor tyrosine-kinase inhibitor CI-1033 in patients with pretreated metastatic breast cancer. Cancer Chemother Pharmacol. doi:10.1007/s00280-009- 0975-z
30. Lykkesfeldt AE, Sorensen EK (1992) Effect of estrogen and antiestrogens on cell proliferation and synthesis of secreted proteins in the human breast cancer cell line MCF-7 and a tamoxifen resistant variant subline, AL-1. Acta Oncol 31:131-138
31. Lundholt BK, Briand P, Lykkesfeldt AE (2001) Growth inhibition and growth stimulation by estradiol of estrogen receptor transfected human breast epithelial cell lines involve different pathways. Breast Cancer Res Treat 67:199-214
32. Holbro T, Beerli RR, Maurer F, Koziczak M, Barbas CFIII, Hynes NE (2003) The E.rbB2/E:rbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation. Proc Natl Acad Sci U S A 100:8933-8938
33. Frankel LB, Lykkesfeldt AE, Hansen JB, Stenvang J (2007) Protein kinase C alpha is a marker for antiestrogen resistance and is involved in the growth of tamoxifen resistant human breast cancer cells. Breast Cancer Res Treat 104:165-179
34. Larsen SS, Madsen MW, Jensen BL, Lykkesfeldt AE (1997) Resistance of human breast-cancer cells to the pure steroidal antiestrogen ICI 182, 780 is not associated with a general loss of estrogen-receptor expression or lack of estrogen responsiveness. Int J Cancer 72:1129-1136
35. Munzone E, Curigliano G, Rocca A, Bonizzi G, Renne G, Goldhirsch A, Nole F (2006) Reverting estrogen-receptor-negative phenotype in HER-2-overexpressing advanced breast cancer patients exposed to trastuzumab plus chemotherapy. Breast Cancer Res 8:R4
36. Larsen SS, Egeblad M, Jaattela M, Lykkesfeldt AE (1999) Acquired antiestrogen resistance in MCF-7 human breast cancer sublines is not accomplished by altered expression of receptors in the ErbB-family. Breast Cancer Res Treat 58:41-56
37. Gee JM, Harper ME, Hutcheson IR, Madden TA, Barrow D, Knowlden JM, McClelland RA, Jordan N, Wakeling AE, Nicholson RI (2003) The antiepidermal growth factor receptor agent gefitinib (ZD1839/Iressa) improves antihormone response and prevents development of resistance in breast cancer in vitro. Endocrinology 144:5105-5117
38. Okubo S, Kurebayashi J, Otsuki T, Yamamoto Y, Tanaka K, Sonoo H (2004) Additive antitumour effect of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib (Iressa, ZD1839) and the antioestrogen fulvestrant (Faslodex, ICI 182, 780) in breast cancer cells. Br J Cancer 90:236-244
39. Arteaga CL, Coronado E, Osborne CK (1988) Blockade of the epidermal growth factor receptor inhibits transforming growth factor alpha-induced but not estrogen-induced growth of hormone-dependent human breast cancer. Mol Endocrinol 2:1064-1069
40. Pietras RJ, Arboleda J, Reese DM, Wongvipat N, Pegram MD, Ramos L, Gorman CM, Parker MG, Sliwkowski MX, Slamon DJ (1995) HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells. Oncogene 10:2435-2446
41. van Agthoven T, van Agthoven TL, Portengen H, Foekens JA, Dorssers LC (1992) Ectopic expression of epidermal growth factor receptors induces hormone independence in ZR-75-1. human breast cancer cells. Cancer Res 52:5082-5088
42. Benz CC, Scott GK, Samp JC, Johnson RM, Tripathy D, Coronado E, Shepard HM, Osborne CK (1992) Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu. Breast Cancer Res Treat 24:85-95
43. Nicholson RI, McClelland RA, Gee JM, Manning DL, Cannon P, Robertson JF, Ellis IO, Blarney RW (1994) Transforming growth factor-alpha and endocrine sensitivity in breast cancer. Cancer Res 54:1684-1689
44. Nicholson RI, McClelland RA, Gee JM, Manning DL, Cannon. P, Robertson JF, Ellis IO, Blarney RW (1994) Epidermal growth factor receptor expression in breast cancer: association with response to endocrine therapy. Breast Cancer Res Treat 29:117-125
45. Citri A, Yarden Y (2006) EGF-ERBB signalling: towards the systems level. Nat Rev Mol Cell Biol 7:505-516
46. Arpino G, Gutierrez C, Weiss H, Rimawi M, Massarweh S, Bharwani L, De PS, Osborne CK, Schiff R (2007) Treatment of human epidermal growth factor receptor 2-overexpressing breast cancer xenografts with multiagent HER-targeted therapy. J Natl Cancer Inst 99:694-705
47. Moulder SL, Arteaga CL (2003) A phase I/II trial of trastuzumab and gefitinib in patients with metastatic breast cancer that overexpresses HER2/neu (ErbB-2). Clin Breast Cancer 4:142-145
48. Sergina NV, Rausch M, Wang D, Blair J, Hann B, Shokat KM, Moasser MM (2007) Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3. Nature 445:437-441
49. Fabian MA, Biggs WHIII, Treiber DK, Atteridge CE, Azimioara MD, Benedetti MG, Carter TA, Ciceri P, Edeen PT, Floyd M, Ford JM, Galvin M, Gerlach JL, Grotzfeld RM, Herrgard S, Insko DE, Insko MA, Lai AG, Lelias JM, Mehta SA, Milanov ZV, Velasco AM, Wodicka LM, Patel HK, Zarrinkar PP, Lockhart DJ (2005) A small molecule-kinase interaction map for clinical kinase inhibitors. Nat Biotechnol 23:329-336
50. Wakeling AE, Dukes M, Bowler J (1991) A potent specific pure antiestrogen with clinical potential. Cancer Res 51:3867-3873
51. Nicholson RI, Hutcheson IR, Hiscox SE, Knowlden JM, Giles M, Barrow D, Gee JM (2005) Growth factor signalling and resistance to selective oestrogen receptor modulators and pure anti-oestrogens: the use of anti-growth factor therapies to treat or delay endocrine resistance in breast cancer. Endocr Relat Cancer 12(Suppl 1):S29-S36
52. Sabnis G, Schayowitz A, Goloubeva O, Macedo L, Brodie A (2009) Trastuzumab reverses letrozole resistance and amplifies the sensitivity of breast cancer cells to estrogen. Cancer Res 69:1416-1428
53. Xia W, Bacus S, Hegde P, Husain I, Strum J, Liu L, Paulazzo G, Lyass L, Trusk P, Hill J, Harris J, Spector NL (2006) A model of acquired autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancer. Proc Natl Acad Sci USA 103:7795-7800
54. Baselga J, Semiglazov V, van Dam P, Manikhas A, Bellet M, Mayordomo J, Campone M, Kubista E, Greil R, Bianchi G, Steinseifer J, Molloy B, Tokaji E, Gardner H, Phillips P, Stumm M, Lane HA, Dixon JM, Jonat W, Rugo HS (2009) Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer. J Clin Oncol 27:2630-2637